WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Anheuser Busch Inbev NV ADR generates 191% more annual revenue ($60.96B vs $20.98B). BUD leads profitability with a 11.9% profit margin vs 9.1%. GEHC appears more attractively valued with a PEG of 1.72. BUD earns a higher WallStSmart Score of 63/100 (C+).

BUD

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 4.7Quality: 5.0

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDOvervalued (-9.4%)

Margin of Safety

-9.4%

Fair Value

$70.63

Current Price

$79.89

$9.26 premium

UndervaluedFair: $70.63Overvalued
GEHCUndervalued (+43.4%)

Margin of Safety

+43.4%

Fair Value

$139.80

Current Price

$63.47

$76.33 discount

UndervaluedFair: $139.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD3 strengths · Avg: 8.3/10
Market CapQuality
$159.00B9/10

Large-cap with strong market position

Operating MarginProfitability
26.7%8/10

Strong operational efficiency at 26.7%

EPS GrowthGrowth
20.3%8/10

Earnings expanding 20.3% YoY

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
14.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

BUD2 concerns · Avg: 4.0/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

Price/BookValuation
10.7x4/10

Trading at 10.7x book value

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.724/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Price/Book.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

GEHC carries more volatility with a beta of 0.87 — expect wider price swings.

BUD is growing revenue faster at 12.0% — sustainability is the question.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BUD scores higher overall (63/100 vs 57/100) and 12.0% revenue growth. GEHC offers better value entry with a 43.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?